<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics; Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics; Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2024-06-17 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics," which provides recommendations for the development of oligonucleotide therapeutics. Specifically, this guidance addresses FDA's current thinking regarding clinical pharmacology considerations and recommendations for oligonucleotide therapeutic development programs, including characteri...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2024-13271</p>
    <p><strong>Publication Date:</strong> 2024-06-17</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2024/06/17/2024-13271/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-guidance">https://www.federalregister.gov/documents/2024/06/17/2024-13271/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-guidance</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2024-13271</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
